Chronic Refractory Cough Pipeline

DelveInsight’s, “Chronic Refractory Cough Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic Refractory Cough pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Refractory Cough Understanding

Chronic Refractory Cough Overview

Chronic refractory cough (CRC) is a persistent cough lasting longer than eight weeks that remains unresolved despite thorough evaluation and treatment of underlying causes such as asthma, gastroesophageal reflux disease, or upper airway cough syndrome. It is increasingly recognized as a disorder of cough hypersensitivity, in which heightened sensitivity of airway sensory nerves leads to an exaggerated cough reflex triggered by otherwise innocuous stimuli such as talking, cold air, or mild irritants. 
It is characterized primarily by a persistent, dry cough lasting more than eight weeks that does not respond to standard treatments for common underlying conditions. Patients often experience frequent coughing bouts triggered by everyday stimuli such as talking, laughing, cold air, strong smells, or eating. A hallmark feature is a heightened cough reflex accompanied by sensations of throat irritation, tickling, or an urge-to-cough feeling (laryngeal paresthesia). Additional symptoms may include hoarseness, throat clearing, and a sensation of something stuck in the throat (globus). 

Chronic refractory cough (CRC) is primarily understood as a disorder of cough hypersensitivity, in which the neural pathways regulating the cough reflex become dysregulated. Repeated airway inflammation or injury often from prior respiratory conditions leads to sensitization of peripheral sensory nerves (particularly vagal afferents) in the airway epithelium. This results in an exaggerated response to otherwise harmless stimuli such as talking, cold air, or mild irritants. At the molecular level, upregulation of receptors such as transient receptor potential (TRP) channels and purinergic P2X3 receptors contributes to heightened neuronal excitability. The etiology of CRC is typically multifactorial and often follows common causes of chronic cough that have either been treated or are no longer active. These include conditions such as asthma, gastroesophageal reflux disease (GERD), upper airway cough syndrome (postnasal drip), and respiratory infections, which may initially trigger the cough reflex. Environmental exposures (e.g., pollutants, smoke), use of medications like ACE inhibitors, and laryngeal dysfunction can also contribute.

The diagnosis of CRC is largely one of exclusion and follows a systematic evaluation of chronic cough lasting more than eight weeks. Clinicians begin with a detailed clinical history, medication review (e.g., ACE inhibitors), and assessment for common underlying causes such as asthma, gastroesophageal reflux disease (GERD), and upper airway cough syndrome. Standard investigations may include chest imaging (X-ray or CT), spirometry or lung function testing, and, when indicated, tests for airway inflammation or reflux. If the cough persists despite appropriate treatment of these conditions and no alternative cause is identified, the diagnosis of CRC is considered. Increasingly, features such as cough hypersensitivity, laryngeal irritation, and heightened response to trivial stimuli support the diagnosis. Treatment of CRC focuses on reducing cough reflex sensitivity and improving quality of life rather than targeting a single underlying disease. Pharmacological management commonly includes neuromodulators such as gabapentin, pregabalin, or low-dose opioids (e.g., morphine) in selected cases, which act on neural pathways involved in cough reflex hypersensitivity. A newer class of therapies, P2X3 receptor antagonists (e.g., gefapixant), directly targets sensory nerve signaling and has shown promising results in reducing cough frequency.

"Chronic Refractory Cough Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Refractory Cough pipeline landscape is provided which includes the disease overview and Chronic Refractory Cough treatment guidelines. The assessment part of the report embraces, in depth Chronic Refractory Cough commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Refractory Cough collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Chronic Refractory Cough Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Refractory Cough R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Refractory Cough.

Chronic Refractory Cough Emerging Drugs Analysis

This segment of the Chronic Refractory Cough report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Refractory Cough Emerging Drugs

Camlipixant: GSK

Camlipixant (formerly BLU-5937) is an investigational, oral, small-molecule receptor antagonist designed to treat refractory chronic cough (RCC) and other hypersensitivity disorders. Phase 2b studies (SOOTHE) show it effectively reduces 24-hour cough frequency by roughly 34% at 50-mg and 200-mg doses compared to placebo, with a favorable safety profile and low rates of taste alteration. As a P2X3 antagonist, it acts on peripheral sensory neurons in the airways to decrease the hypersensitivity that causes chronic coughing. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Chronic Refractory Cough.

Further product details are provided in the report……..

Chronic Refractory Cough Drug Therapeutic Assessment

This segment of the report provides insights about the different Chronic Refractory Cough drugs segregated based on following parameters that define the scope of the report, such as:

Major Chronic Refractory Cough Players in Chronic Refractory Cough

There are approx. 5+ key companies which are developing the therapies for Chronic Refractory Cough. The companies which have their Chronic Refractory Cough drug candidates in the most advanced stage, i.e. Phase III include, GSK.

Chronic Refractory Cough Clinical Trial Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Chronic Refractory Cough Drug Route of Administration

Chronic Refractory Cough pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Chronic Refractory Cough Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Chronic Refractory Cough Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Refractory Cough Clinical Trial Activities

The Chronic Refractory Cough Pipeline report provides insights into different Chronic Refractory Cough Clinical Trial within phase II, I, preclinical and discovery stage. It also analyses Chronic Refractory Cough therapeutic drugs key players involved in developing key drugs.

Chronic Refractory Cough Pipeline Development Activities

The Chronic Refractory Cough Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Refractory Cough drugs.

Chronic Refractory Cough Pipline Report Insights

• Chronic Refractory Cough Pipeline Analysis
• Chronic Refractory Cough Therapeutic Assessment
• Chronic Refractory Cough Unmet Needs
• Impact of Chronic Refractory Cough Drugs

Chronic Refractory Cough Pipeline Report Assessment

• Chronic Refractory Cough Pipeline Product Profiles
• Chronic Refractory Cough Therapeutic Assessment
• Chronic Refractory Cough Pipeline Assessment
• Chronic Refractory Cough Inactive drugs assessment
• Chronic Refractory Cough Market Unmet Needs

Key Questions Answered In the Chronic Refractory Cough Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Chronic Refractory Cough drugs?
• How many Chronic Refractory Cough drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Refractory Cough?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Refractory Cough therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Chronic Refractory Cough and their status?
• What are the key designations that have been granted to the emerging drugs?

Chronic Refractory Cough Key Players

• GSK
• Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
• Trevi Therapeutics

Chronic Refractory Cough Key Products

• Camlipixant
• HW091077
• Haduvio